Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
Sean Virani(University of British Columbia), Lynn Straatman(University of British Columbia), Nowell M. Fine(University of Calgary), Nola Wurtele(University of British Columbia), Igal A. Sebag(Inserm), Sean Hopkins(Washington State Department of Ecology), Christine Brezden‐Masley(Mount Sinai Hospital), Anil A. Joy(University of Alberta), Julie Lemieux(Université Laval), Christine Simmons(BC Cancer Agency), Susan Dent(Government of the United States of America), Margot K. Davis(University of British Columbia), Brian Clarke(MedStar Washington Hospital Center), Marc André Côté(Centre hospitalier de l'Université Laval), Bradley D. Hayley(Ottawa Hospital), D. Ian Paterson(University of Ottawa), Daniel Rayson, Paaladinesh Thavendiranathan(University of Toronto), Davinder S. Jassal(St. Boniface Hospital), Ellamae Stadnick(University of Ottawa), Christopher Johnson(University of Ottawa), Haissam Haddad(St. Michael's Hospital), Kishore Thain(Queen's University), Jason Wentzell(Ottawa Hospital), Jeffrey Sulpher(BC Cancer Agency)
Cited by 234
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589